Here's What Analysts Are Asking Puma Biotech Following Roche's Positive Perjeta Results

By: via Benzinga
RBC Capital says the commercial opportunity for Puma Biotechnology Inc (NASDAQ: PBYI)’s breast cancer drug neratinib in the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.